XKH001 Injection in Healthy Subjects

Summary

This study is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) clinical study. The primary objective is to evaluate the safety, tolerability, and PK of multiple SC doses of XKH001 in healthy subjects.

Timeline

Start

2023-05-12

Primary completion

2024-02-20

Completion

2024-03-29

Publications

• Zhang H, Zheng W, Peng R, Wu D, Hu Y, Sun T, Gao L, Liu Y, Guo L, Ding Y, Liu L. First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers. Expert Opin Investig Drugs. 2025 Jan-Feb;34(1-2):81-87. doi: 10.1080/13543784.2025.2453162. Epub 2025 Jan 20.

Drugs

Indications